Switch to RAL-containing regimen
CHEER Study: Switch ENF to RAL
Original article : J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):367-73 – W Towner
Last update :
28/03/2014
Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK
- Replacing ENF with RAL in treatment-experienced HIV-infected patients with sustained viral suppression is safe and efficacious
- Pilot, open-label study
- 52 adults on salvage therapy with enfuvirtide-based regimen and HIV-1 RNA < 75 c/mL (bDNA) or < 50 c/mL (PCR) for at least 6 months
- Switch of enfuvirtide to RAL 400 mg bid, the remainder of the salvage regimen being unchanged. At the time of the switch:
- Mean length of time on prior ARV therapy: 15 years
- ENF had been administered for a median of 2.7 years
- Salvage regimen containing a PI/r in 47 patients (90%)
- Baseline CD4 cell count: 377/mm3
- Virologic and immunologic outcomes at week 24 (intent-to-treat analysis)
- HIV-1 RNA below the limit of quantification, N = 49 (94%)
- Treatment failures, N = 3
- Withdrew consent N = 1
- Virologic failure N = 1
- Death N = 1
- Average CD4 cell count change: + 32/mm3
- No grade 3 or 4 laboratory abnormalities
- No adverse event leading to discontinuation of RAL
- Patient treatment satisfaction significantly improved on RAL
Back to Table of Contents
Download the slides
